Tranexamic acid (Acidum tranexamicum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Inhibitors of fibrinolysis

Included in the formulation
  • GEMTRANIKS
    solution in / in 
    FarmSirma Soteks, ZAO     Russia
  • Sanssamik
    solution in / in 
    SP.INKOMED, ​​LLC     Russia
  • Sanssamik
    pills inwards 
    SP.INKOMED, ​​LLC     Russia
  • Stagemine
    solution in / in 
    NOVOSIBHIMFARM, OJSC     Russia
  • Traxara
    solution in / in 
    VEROPHARM SA     Russia
  • Tramzon
    solution in / in 
    Novator Pharma, LLC     United Kingdom
  • Tranexam®
    solution in / in 
    NIZHFARM, JSC     Russia
  • Tranexam®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Tranexam®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Tranexam®
    solution in / in 
    NIZHFARM, JSC     Russia
  • Tranexamic acid
    solution in / in 
    TRIVIUM-XXI, LLC     Russia
  • Tranexamic acid-SOLOfarm
    solution in / in 
    GROTEKS, LLC     Russia
  • Tranexolone®
    solution in / in 
    EKOFARMPLUS, CJSC     Russia
  • Troxaminate
    solution in / in 
    Hilton Pharma (Pvt) Ltd.     Pakistan
  • Troxaminate
    capsules inwards 
    Hilton Pharma (Pvt) Ltd.     Pakistan
  • Cyclogemal
    pills inwards 
    OTISIFARM, OJSC     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    B.02.A.A   Amino acids

    B.02.A.A.02   Tranexamic acid

    Pharmacodynamics:

    Competitive inhibition of plasminogen activation, in high doses, suppresses plasmin activity.

    Pharmacokinetics:

    Absorption is 30-50%.Connection with plasma proteins <3%. Biotransformation <5%. The elimination half-life is 2 hours. Elimination by the kidneys (the main way is glomerular filtration) is 90% unchanged.

    Indications:

    Bleeding or risk of bleeding in the background:

    - increased local fibrinolysis (uterine, including von Willebrand disease and other coagulopathy, nasal, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, conization of the cervix, about tooth extraction in patients with hemorrhagic diathesis);

    - strengthening of generalized fibrinolysis (malignant neoplasms of the pancreas and prostate gland, operations on the thoracic organs, postpartum haemorrhages, manual detachment, leukemia, liver disease).

    Bleeding during pregnancy.

    Hereditary angioedema, allergic diseases.

    Inflammatory diseases (tonsillitis, pharyngitis, laryngitis, stomatitis, aphthae of the oral mucosa).

    ICD-10

    II.C15-C26.C25   Malignant neoplasm of pancreas

    II.C60-C63.C61   Malignant neoplasm of prostate

    III.D65-D69.D69.3   Idiopathic thrombocytopenic purpura

    XI.K20-K31.K25.0   Gastric ulcer acute with bleeding

    XI.K20-K31.K26.0   Duodenal ulcer acute with bleeding

    XIV.N80-N98.N93.9   Abnormal uterine and vaginal bleeding, unspecified

    XV.O20-O29.O20   Bleeding in early pregnancy

    XV.O60-O75.O72   Postpartum hemorrhage

    XVIII.R30-R39.R31   Nonspecific hematuria

    XIX.T80-T88.T81.0   Bleeding and hematoma complicating the procedure, not elsewhere classified

    Contraindications:

    Hypersensitivity; Subarachnoid hemorrhage (increased risk of cerebral ischemia).

    Carefully:

    Thrombohemorrhagic complications (in combination with heparin and indirect anticoagulants), thromboses or the threat of their development; renal failure, impaired color vision, pregnancy.

    Pregnancy and lactation:

    Tranexamic acid penetrates the placenta: after intravenous administration of 10 mg / kg, a concentration of 30 μg / ml (190.8 μmol / L) is created in fetal blood plasma, but no controlled studies have been performed on humans. At the same time, healthy mothers were born from mothers who received tranexamic acid for fibrinolytic bleeding or bleeding during placental detachment.Penetrates into breast milk in concentrations corresponding to approximately 1% of the concentration in the blood plasma of the mother.

    Recommendations for FDA - Category B.

    Dosing and Administration:

    Intravenous (drip, jet). When generalized fibrinolysis is administered in a single dose of 15 mg / kg body weight every 6-8 hours, the rate of administration is 1 ml / min. With local fibrinolysis, the administration of the drug in a dose of 250-500 mg 2-3 times a day is recommended. When prostatectomy or surgery on the bladder is administered during the operation, 1 g, then 1 g every 8 hours for 3 days, after which they switch to the inside of the tablet form until the disappearance of the macrohematuria.

    Side effects:

    Allergic reactions (rash, skin itch, urticaria), dyspeptic phenomena (anorexia, nausea, vomiting, heartburn, diarrhea), dizziness, weakness, drowsiness, tachycardia, chest pain, hypotension (with rapid intravenous injection), color vision, blurred vision; thrombosis or thromboembolism (the risk of development is minimal).

    Overdose:

    No data.

    Interaction:

    Pharmaceutically incompatible with blood products, solutions containing penicillin, urokinase,hypertensive drugs (norepinephrine, deoxyepinefrin hydrochloride, metarterin bitartrate), tetracyclines, dipyridamole, diazepam. Hemostatic preparations, hemocoagulase potentiate the activation of thrombogenesis.

    Special instructions:

    When combined with hemostatic drugs and hemocoagulase, thrombus formation can be activated. Before and during the treatment it is necessary to conduct an examination of the oculist (visual acuity, color vision, eye fundus).

    Instructions
    Up